SCHEMBL434743

SCHEMBL434743

CCCN(C)c1ccccn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 4/20 0.56
CYP2C19 P33261 2/20 0.56
KCNH2 Q12809 4/20 0.49
KCNA5 P22460 2/20 0.49
CHRM2 P08172 3/20 0.47
ADRA2A P08913 3/20 0.47
DRD1 P21728 3/20 0.47
SLC6A2 P23975 3/20 0.47
SLC6A4 P31645 3/20 0.47
SLC6A3 Q01959 3/20 0.47
ADRA1A P35348 2/20 0.47
ADRA2B P18089 2/20 0.47
HTR2A P28223 2/20 0.47
HRH1 P35367 2/20 0.47
ADRA2C P18825 1/20 0.47
OPRK1 P41145 1/20 0.47
HCAR3 P49019 1/20 0.47
CSNK1D P48730 1/20 0.47
MAPK11 Q15759 1/20 0.47
MAPK14 Q16539 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5379223 0.98 CYP2D6 (0.55) CYP2D6CYP2C19KCNH2KCNA5CHRM2
SCHEMBL6439932 0.89 CYP2D6 (0.53) CYP2D6CYP2C19KCNH2KCNA5CHRM2
SCHEMBL13220768 0.85 CYP2D6 (0.50) CYP2D6CYP2C19KCNH2KCNA5CHRM2
SCHEMBL11260775 0.85 CYP2D6 (0.50) CYP2D6CYP2C19KCNH2KCNA5CHRM2
SCHEMBL4445537 0.84 CYP2D6 (0.72) CYP2D6CYP2C19KCNH2CHRM2ADRA2A
SCHEMBL2760196 0.83 CYP2D6 (0.55) CYP2D6CYP2C19KCNH2KCNA5CHRM2
Alcohol SCHEMBL7553089 0.83 POLB (0.54) CYP2D6CYP2C19KCNH2CHRM2ADRA2A
SCHEMBL14748423 0.83 CYP2D6 (0.51) CYP2D6CYP2C19KCNH2KCNA5CHRM2
SCHEMBL844392 0.82 CYP2D6 (0.55) CYP2D6CYP2C19KCNH2CHRM2ADRA2A
SCHEMBL440638 0.82 POLB (0.58) CYP2D6CYP2C19KCNH2CHRM2ADRA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107955107-B Method for preparing star polyacrylamide by single electron transfer living radical polymerization 东北石油大学 2020-12-29 CN claimed
US-11666658-B2 Rifamycin analogs and antibody-drug conjugates thereof Regeneran Pharmaceuticals, Inc. (US) 2023-06-06 US disclosed
CN-107955107-B Method for preparing star polyacrylamide by single electron transfer living radical polymerization 东北石油大学 2020-12-29 CN disclosed
US-20200368361-A1 RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2020-11-26 US disclosed
WO-2020132483-A1 RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2020-06-25 WO disclosed
EP-2596062-B1 SET-LRP POLYMERIZATION OF ACRYLATES IN THE PRESENCE OF ACIDS ROHM & HAAS (US) 2019-09-18 EP disclosed
US-10273314-B2 Set-LRP polymerization of acrylates in the presence of acids ROHM AND HAAS COMPANY (US) 2019-04-30 US disclosed
US-20130245216-A1 SET-LRP POLYMERIZATION OF ACRYLATES IN THE PRESENCE OF ACIDS THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) 2013-09-19 US disclosed
EP-2596062-A1 SET-LRP POLYMERIZATION OF ACRYLATES IN THE PRESENCE OF ACIDS Rohm and Haas Company (US) 2013-05-29 EP disclosed
CN-103119098-A SET-LRP Polymerization of Acrylic Compounds in the Presence of Acid ROHM & HAAS 2013-05-22 CN disclosed
WO-2012012705-A1 SET-LRP POLYMERIZATION OF ACRYLATES IN THE PRESENCE OF ACIDS ROHM AND HAAS COMPANY (US) 2012-01-26 WO disclosed
EP-0949230-B1 PROCESSES FOR PRODUCING ALKENYL-SUBSTITUTED AROMATIC HYDROCARBONS SUMITOMO CHEMICAL CO (JP) 2005-07-27 EP disclosed
US-6403852-B1 CATALYTIC ALKENYLATION OF ALKYL-SUBSTITUTED AROMATIC HYDROCARBON HAVING HYDROGEN ATOM AT ALPHA-POSITION OF SIDE CHAIN THEREOF WITH CONJUGATED DIENE SUMITOMO CHEMICAL CO., LIMITED (JP) 2002-06-11 US disclosed
EP-0949230-A1 PROCESSES FOR PRODUCING ALKENYL-SUBSTITUTED AROMATIC HYDROCARBONS SUMITOMO CHEMICAL COMPANY LIMITED (JP) 1999-10-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200368361-A1 RIFAMYCIN ANALOGS AND ANTIBODY-DRUG CONJUGATES THEREOF ASGR1, CUTA, SRPRA CYP2D6 1391/4885CYP2C19 2413/4885KCNH2 4322/4885
US-11666658-B2 Rifamycin analogs and antibody-drug conjugates thereof ASGR1, CUTA, SRPRA CYP2D6 1391/4885CYP2C19 2413/4885KCNH2 4322/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.